home / stock / mrna / mrna quote
Last: | $129.06 |
---|---|
Change Percent: | 0.65% |
Open: | $127.49 |
Close: | $129.06 |
High: | $129.2 |
Low: | $124.98 |
Volume: | 2,941,740 |
Last Trade Date Time: | 05/15/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$129.06 | $127.49 | $129.06 | $129.2 | $124.98 | 2,941,740 | 05-15-2024 |
$128.32 | $127 | $128.32 | $129.9399 | $126.3385 | 3,567,495 | 05-14-2024 |
$125.67 | $119.47 | $125.67 | $126.88 | $119.03 | 4,095,239 | 05-13-2024 |
$117.31 | $120.75 | $117.31 | $124.9 | $116.7317 | 4,238,508 | 05-10-2024 |
$122.69 | $123.15 | $122.69 | $125.5 | $121.68 | 3,367,379 | 05-09-2024 |
$121.89 | $120 | $121.89 | $122.825 | $119.5 | 2,505,444 | 05-08-2024 |
$121.07 | $122.86 | $121.07 | $123.5 | $118.68 | 2,894,011 | 05-07-2024 |
$122.13 | $125 | $122.13 | $125.15 | $118.75 | 3,936,464 | 05-06-2024 |
$125 | $125 | $125 | $126.4 | $122.01 | 4,513,133 | 05-03-2024 |
$125.59 | $114.86 | $125.59 | $128.81 | $114.06 | 11,973,082 | 05-02-2024 |
$111.46 | $111.11 | $111.46 | $113.73 | $109 | 3,814,699 | 05-01-2024 |
$110.31 | $110.5 | $110.31 | $113.21 | $109.55 | 3,211,988 | 04-30-2024 |
$111.62 | $108.78 | $111.62 | $112.33 | $108.72 | 2,610,736 | 04-29-2024 |
$107.97 | $106.18 | $107.97 | $108.19 | $105.25 | 2,247,093 | 04-26-2024 |
$106.18 | $107.43 | $106.18 | $108.23 | $103.52 | 2,798,459 | 04-25-2024 |
$108.85 | $111.05 | $108.85 | $111.29 | $106.64 | 3,391,275 | 04-24-2024 |
$107.89 | $104.46 | $107.89 | $108.21 | $103.48 | 2,392,766 | 04-23-2024 |
$104.46 | $102.79 | $104.46 | $105.43 | $99.3 | 3,176,356 | 04-22-2024 |
$101.41 | $102.37 | $101.41 | $103.795 | $100.45 | 2,670,446 | 04-19-2024 |
$102 | $102.53 | $102 | $103.505 | $99.9 | 1,798,498 | 04-18-2024 |
News, Short Squeeze, Breakout and More Instantly...
On CNBC's “Mad Money Lightning Round,” Jim Cramer believes in Moderna, Inc. (NASDAQ:MRNA). On May 14, Evercore ISI Group analyst C...
2024-05-14 06:35:00 ET Investors have put their hopes in Moderna 's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it represents a new revenue stream for a company that until now has relied on just one product, and a product strugg...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 27.7% on an annualized basis producing an average annual return of 40.43...